3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
50
Carcinoma, Non-Small-Cell Lung
39
Carcinoma, Renal Cell
28
Carcinoma, Hepatocellular
18
Neoplasm Metastasis
16
Neoplasms
15
Colorectal Neoplasms
15
Stomach Neoplasms
13
Lung Neoplasms
13
Adenocarcinoma Of Esophagus
11
Squamous Cell Carcinoma of Head and Neck
10
Carcinoma, Transitional Cell
8
Brain Neoplasms
8
Hodgkin Disease
7
Skin Neoplasms
6
Sarcoma
6
Kidney Neoplasms
6
Esophageal Neoplasms
6
Triple Negative Breast Neoplasms
5
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Clear-cell metastatic renal cell carcinoma
5
Carcinoma, Merkel Cell
5
Uveal Melanoma
4
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Recurrence
4
Neuroendocrine Tumors
4
Nasopharyngeal Carcinoma
4
Mesothelioma
4
Interventions
belzutifan
3
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Propranolol
1
Nivolumab
1
Everolimus
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
von Hippel-Lindau Disease
×
Nivolumab
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled